Natalia Luraguiz
Family Medicine · Shreveport, LANPI 1639465065
Payments from drug & device makers
Across 225 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$2K
- Amgen$985
- AstraZeneca$513
- Novo Nordisk$400
- Boehringer Ingelheim$240
- Merck$225
- plus $870 from 14 others
What the payments were for
- Food & beverage$5,108100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 10 | $1,894 |
| Amgen | 77 | $985 |
| AstraZeneca | 23 | $513 |
| Novo Nordisk | 27 | $400 |
| Boehringer Ingelheim | 14 | $240 |
| Merck | 19 | $225 |
| AbbVie(2 entities) | 11 | $186 |
| Lilly USA, LLC | 8 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $128 |
| Pfizer | 6 | $95 |
| Novartis | 5 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Astellas Pharma US Inc | 4 | $55 |
| Radius Health, Inc. | 2 | $33 |
| GSK | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Itamar Medical Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,126 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 52 | $53,379 |
| OzempicSemaglutide | 46 | $45,454 |
| Repatha SureclickEvolocumab | 45 | $27,595 |
| XareltoRivaroxaban | 18 | $19,530 |
| LinzessLinaclotide | 21 | $10,996 |
| MyrbetriqMirabegron | 12 | $5,515 |
| Icosapent Ethyl | 11 | $1,659 |
| PaxlovidNirmatrelvir/Ritonavir | 13 | $1,429 |
| SynthroidLevothyroxine Sodium | 15 | $1,144 |
| Ezetimibe | 22 | $890 |
| Metoprolol Succinate | 45 | $809 |
| Eszopiclone | 27 | $702 |
| Pantoprazole Sodium | 61 | $645 |
| Rosuvastatin Calcium | 64 | $640 |
| Gabapentin | 57 | $569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $146 | $53,37952 claims |
| Novo NordiskOzempic | $400 | $45,45446 claims |
| AbbVieLinzess, Synthroid | $186 | $12,14036 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $5,51512 claims |
| PfizerPaxlovid | $95 | $1,42913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Shreveport
- Michael FlemingShreveport$165K
- David NelsonShreveport$59K
- Krishna SinghShreveport$22K
- Larry FlakeShreveport$20K
- Russell CarrShreveport$17K
- Richard KammShreveport$17K
- Wendy MosesShreveport$16K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.